Coya 10-Q Flags Going Concern: $35.8M Cash, $86.4M Deficit, $10.6M Q3 Loss
COYA sits 20% above its 52-week low of $2.72.
Summary
Coya's Q3 10-Q carries an explicit going-concern warning: $35.8 million of cash against an $86.4 million accumulated deficit and a $10.6 million quarterly loss, with the ALSTARS ALS readout in early Q2 2027 now the gating event for the runway.
Key Events · Earnings and Guidance · COYA
-
Going-Concern Warning Disclosed
The 10-Q states Coya does not have sufficient cash to support operations for more than one year from issuance and that substantial doubt exists about its ability to continue as a going concern, with an accumulated deficit of $86.4 million.
-
Q3 Loss Widens on ALS Spending
Net loss was $10.6 million for the three months ended September 30, 2026 versus $2.1 million a year earlier; R&D rose to $8.6 million from $2.9 million, including $6.8 million of COYA 302-ALS external costs.
-
Cash Covers Into Second Half 2027
Cash and cash equivalents were $35.8 million at September 30, 2026, down from $46.8 million at December 31, 2025; nine-month operating cash use was $20.8 million versus $9.7 million a year earlier.
-
ATM Is the Only Live Financing
A $30.0 million at-the-market Sales Agreement with Leerink dated May 12, 2026 remains fully unused, with $30.0 million available; the January 2026 private placement of 2,522,727 shares at $4.40 raised about $11.1 million gross.
Analysis · COYA · Life Sciences
The Q3 numbers were already out this morning via 8-K, but the 10-Q is where the formal going-concern language lives: management states it does not have enough cash to fund operations for more than one year from the issuance date, despite $35.8 million on hand and a stated runway into the second half of 2027. That runway depends on the ALSTARS Phase 2/3 readout in early Q2 2027 landing before the money runs out, and on raising more capital — the only live facility is a $30.0 million at-the-market program with nothing sold yet. Burn is accelerating hard: nine-month operating cash use of $20.8 million versus $9.7 million a year earlier, driven by COYA 302 ALS trial costs. For a clinical-stage company whose entire thesis rests on one trial, a going-concern paragraph plus a widening loss is the kind of disclosure that resets how much risk the equity carries.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COYA was trading at $3.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.1M. The 52-week trading range was $2.72 to $6.62. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.